Nextech3D.ai - CEO, Evan Gappelberg.
CEO, Evan Gappelberg.
Source: YouTube.
  • Nextech AR (NTAR) announces a share purchase agreement with an institutional investor for gross proceeds of approximately $10 million
  • The company will issue 8,130,082 common shares and warrants
  • H.C. Wainwright & Co. is acting as the exclusive agent for the offering
  • The net proceeds will be used for working capital and general corporate purposes
  • The private placement is expected to close on or about January 25
  • Nextech AR is a leader in the rapidly growing augmented reality industry
  • Nextech AR Solutions (NTAR) opened trading at C$1.39 per share

Nextech AR (NTAR) has announced a private placement with an institutional investor for gross proceeds of approximately $10 million.

The company will issue 8,130,082 common shares and warrants priced at $1.23 per share.

Each share purchase warrant will entitle the holder to purchase one additional common share at an exercise price of $1.54 for a period of three years.

Nextech AR Solutions is bringing augmented reality (AR) to the masses by creating an AR ecosystem featuring eCommerce solutions for websites, AR learning and education as well as AR live streaming for events.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the placement.

The net proceeds of the private placement will be used for working capital and general corporate purposes. 

The private placement is expected to close on or about January 25, 2022, subject to satisfaction of customary closing conditions.

Nextech AR Solutions (NTAR) opened trading at C$1.36 per share.

More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.